S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
NASDAQ:OPT

Opthea Stock Forecast, Price & News

$6.28
+0.08 (+1.29%)
(As of 12/7/2021 03:45 AM ET)
Add
Compare
Today's Range
$6.28
$6.28
50-Day Range
$6.20
$8.04
52-Week Range
$6.07
$16.23
Volume
2,476 shs
Average Volume
39,942 shs
Market Capitalization
$275.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.13
30 days | 90 days | 365 days | Advanced Chart
Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.


Opthea logo

About Opthea

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$70 thousand
Book Value
$3.08 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$275.69 million
Optionable
Not Optionable

Company Calendar

Today
12/07/2021
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1258th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

186th out of 202 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Opthea (NASDAQ:OPT) Frequently Asked Questions

Are investors shorting Opthea?

Opthea saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 97,400 shares, a drop of 36.8% from the October 14th total of 154,000 shares. Based on an average trading volume of 12,400 shares, the short-interest ratio is presently 7.9 days.
View Opthea's Short Interest
.

Who are Opthea's key executives?

Opthea's management team includes the following people:
  • Dr. Megan Baldwin M.A.I.C.D., Ph.D., MAICD, MD, CEO & Exec. Director (Age 46, Pay $446.85k)
  • Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICD, CFO & Company Sec. (Age 54, Pay $265.67k)
  • Ms. Annie Lee, Fin. & Operations Mang.
  • Dr. Richard Chadwick, Head of Intellectual Property (Age 55)
  • Dr. Michael Gerometta, Head of Chemistry, Manufacturing & Controls Devel. (Age 57)
  • Ms. Karen Adams, VP of Fin. & Company Sec.
  • Dr. Ian Leitch, Director of Clinical Research (Age 58)
  • Dr. James Goding, Independent Consultant

When did Opthea IPO?

(OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

What is Opthea's stock symbol?

Opthea trades on the NASDAQ under the ticker symbol "OPT."

Who are Opthea's major shareholders?

Opthea's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (3.36%) and Millennium Management LLC (0.42%).

Which institutional investors are selling Opthea stock?

OPT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.

Which institutional investors are buying Opthea stock?

OPT stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc..

How do I buy shares of Opthea?

Shares of OPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately $6.28.

How much money does Opthea make?

Opthea has a market capitalization of $275.69 million and generates $70 thousand in revenue each year.

What is Opthea's official website?

The official website for Opthea is www.opthea.com.

Where are Opthea's headquarters?

How can I contact Opthea?

Opthea's mailing address is LEVEL 4 650 CHAPEL STREET, SOUTH YARRA VICTORIA C3, 3141. The company can be reached via phone at 61-3-9826-0399.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.